Investor Alert

London Markets Open in:

Jan. 19, 2022, 12:24 p.m. EST

4 Penny Stocks To Buy For Under $4 Right Now

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    ReTo Eco-Solutions Inc. (RETO)
  • X
    Oncolytics Biotech Inc. (ONCY)
  • X
    ADMA Biologics Inc. (ADMA)

or Cancel Already have a watchlist? Log In

I won't give a history lesson on the stock, but it is worth noting and something still relevant right now, in my opinion. This week ADMA continued its climb after several key updates. The first involved receipt of FDA approval for another plasma collection center. Its South Carolina facility met the International Quality Plasma Program Certification criteria, which added to its growing list of approved locations to 4.

Read: Trading Penny Stocks? Top Stock Market News For January 19th, 2022

"With broader industry plasma collection headwinds anticipated to persist in early 2022 due to COVID-19 and other factors, ADMA believes its uniquely strong plasma supply position will support the continued acquisition of new customers in the in the supply-constrained U.S. immunoglobulin market." - Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager, ADMA BioCenters.

Adding to this was interest stemming from the company's latest business update. In particular, interim Q4 sales are expected to come in higher than expected. "Following the successful establishment of end-to-end control of its most critical manufacturing and supply chain functions, coupled with a substantial expansion of its production capacity, 2021 was a foundational year for ADMA, culminating in a year-exiting annualized revenue run rate over $100 million," said Adam Grossman, President, and CEO.

4. Dare Bioscience /zigman2/quotes/203460984/composite DARE -4.07%

Dare stock has retraced back to its 200-day moving average this week. But interestingly enough, prices have consistently held at this level for four consecutive sessions. Attention may have come back to the company as it has recently presented at the HC Wainwright BIOCONNECT Conference. CEO Sabrina Martucci Johnson attended the conference and gave a presentation on the company.

Late last year, DARE stock surged after it was revealed that the FDA approved its ZXACIATO vaginosis treatment. David Friend, Ph.D., Dare's Chief Scientific Officer, also noted that "Now that we have achieved this important demonstration of this drug delivery hydrogel platform technology, we are actively exploring the opportunity to leverage it across other unmet needs in women's health."

With this approval, attention may be focusing on the company's next steps for the treatment.

Penny Stocks To Buy Now?

After seeing the latest catalysts and market momentum, are these still penny stocks to buy now, or is the run over? I'll leave that up to you to decide. However, as the stock market has failed to regain losses due to new rate concerns, cheap stocks have grown in popularity this month. Though the stakes are high, the rewards can be incredible if you know how to trade. If you're new to trading, check out some of these articles to get you caught up with some of the basics:

  • Former Hedge Fund Trader Teachs How To Trade Like Wall Street Pros

  • 10 Secret Ways To Find The Best Penny Stocks To Buy In 2022

  • How to Buy Good Penny Stocks In 2022: Tips & Tricks For New Traders

  • Penny Stocks & 5 Stats To Know If You're Trading Or Investing

  • Trading Penny Stocks? 7 Things to Know For Beginners

  • Penny Stocks Definition & 3 Trading Strategies To Master In 2022

If you enjoyed this article and you're interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

US : U.S.: Nasdaq
$ 1.18
-0.05 -4.07%
Volume: 498,513
Aug. 11, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$104.19 million
Rev. per Employee

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.